Protocol Ledger

NCT06680830 · Phase II · RECRUITING

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Interventional Phase II clinical trial protocol NCT06680830 sponsored by Neuron23 in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-17 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06680830
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06680830
Protocol FieldVerified Registry Value
NCT IdentifierNCT06680830
Consolidated Lead SponsorNeuron23
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2025-01-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI